Deverji's disease after COVID-19: Case report

Abstract

Deverji's disease is a rare idiopathic skin disease characterized by keratinization disorder and manifested in follicular hyperkeratosis, orange-red peeling plaques, palmar-plantar keratodermia with the possible development of erythroderma. The etiopathogenesis of this dermatosis is still unknown. There are such possible trigger factors as traumatization, ultraviolet radiation, taking certain medications, autoimmune and oncological diseases, bacterial or viral infection, vaccination. The presence of familial cases is due to a mutation in the CARD14 gene. Diagnosis of the disease is based on characteristic clinical symptoms. The histological picture has no pathognomonic features; however, a biopsy is necessary for differential diagnosis with other papulosquamous dermatoses. Treatment of Deverji's disease remains a difficult task, since the disease pathogenesis has not been fully studied.

The article describes a clinical case of Deverji's disease manifestation in a 64-year-old woman who had suffered COVID-19 infection twice. She was admitted to the Department of Dermatology and Venerology (Sechenov University) with complaints of skin rashes on her face, trunk, upper and lower extremities, accompanied by severe itching. The absence of any distinctive clinical and histological changes, the torpidity of the skin process and resistance to the therapy made it difficult to make a diagnosis. After the emergence of characteristic clinical symptoms (palmar-plantar keratodermia, salmon-tinged rashes with islands of healthy skin), as well as the results of repeated histological examination (alternating areas of ortho- and parakeratosis; uneven granular layer; vacuolization of basal cells; uneven broad acantholytic strands; loosened dermo-epidermal junction; small perivascular lymph-macrophage infiltrates) Deverji's disease was diagnosed.

The use of standard therapies (systemic glucocorticosteroid therapy, methotrexate, topical therapy) did not give any results, and therefore it was decided to initiate the netakimab. After 5 injections, the first positive results were obtained in the form of the color paling and a decrease in the number of rashes, palmar-plantar keratodermia regression and improvement of the patient psychoemotional state. After 11 injections, almost complete remission was achieved, and treatment was continued until all symptoms disappeared completely.

The article provides a literature review of the etiopathogenesis, clinical manifestations and treatment methods of Deverji's disease. The described clinical case is the fifth example in the world of the Deverji's disease manifestation after a COVID-19 infection, and is also the first case of the IL-17 inhibitor netakimab successful use for the disease treatment.

Keywords

Deverji's disease / COVID-19 / netakimab / inhibitor netakimab

References

[1] Pityriasis pityriasis red papillary hair. Clinical Recommendations of the Russian Federation 2013-2017 (Russia). (In Russ). Available from: https://diseases.medelement.com/disease/питириаз-красный-отрубевидный-волосяной-рекомендации-рф/15247?ysclid=ls37ytpr7f810784853. Accessed: 15.01.2024.

[2] Питириаз красный отрубевидный волосяной. Клинические рекомендации РФ 2013-2017 (Россия). Режим доступа: https://diseases.medelement.com/disease/питириаз-красный-отрубевидный-волосяной-рекомендации-рф/15247?ysclid=ls37ytpr7f810784853. Дата обращения: 15.01.2024.

[3] Borzova EY, Vertieva EY, Grabovskaya OV, et al. Illustrated guide to dermatology. For preparation of doctors for accreditation. Ed. by O.Y. Olisova, N.P. Teplyuk. Moscow: GEOTAR-Media; 2023. 376 p. (In Russ). EDN: YEPGAA doi: 10.33029/9704-7375-7-DER-2023-1-376

[4] Борзова Е.Ю., Вертиева Е.Ю., Грабовская О.В., и др. Иллюстрированное руководство по дерматологии. Для подготовки врачей к аккредитации / под ред. О.Ю. Олисовой, Н.П. Теплюк. Москва: ГЭОТАР-Медиа, 2023. 376 с. EDN: YEPGAA doi: 10.33029/9704-7375-7-DER-2023-1-376

[5] Bonnier E. Traite theorique et pratique des preuves en droit civil et en droit criminel. Vol. 2. 4 ed. Henri Plon, Editeur: Maresq aine, Editeur; 1873. 572 p.

[6] Bonnier E. Traite theorique et pratique des preuves en droit civil et en droit criminel. Vol. 2. 4 ed. Henri Plon, Editeur: Maresq aine, Editeur, 1873. 572 p.

[7] Griffiths A. Edited version of the dowling oration delivered to the British Association of Dermatologists in Liverpool, England, March 2003. Available from: https://prpsurvivalguide.org/wp-content/uploads/2017/05/Dowling-Oration-2003-Liverpool-England.pdf. Accessed: 15.01.2024.

[8] Griffiths A. Edited version of the dowling oration delivered to the British Association of Dermatologists in Liverpool, England, March 2003. Режим доступа: https://prpsurvivalguide.org/wp-content/uploads/2017/05/Dowling-Oration-2003-Liverpool-England.pdf. Дата обращения: 15.01.2024.

[9] Devergie MG. Pityriasis pilaris, maladie de peau non décrite par les dermatologists. Gazette Hebdomadaire de médicine et de chirurgie. 1856;3:197-201.

[10] Devergie M.G. Pityriasis pilaris, maladie de peau non décrite par les dermatologists // Gazette Hebdomadaire de médicine et de chirurgie. 1856. Vol. 3. P. 197-201.

[11] Olisova OY, Fedina AV. Deverzhi disease: Etiology, pathogenesis, clinic, treatment. Russian journal of skin and venereal diseases. 2017;20(2):112. (In Russ). EDN: WALKSW

[12] Олисова О.Ю., Федина А.В. Болезнь Девержи: этиология, патогенез, клиника, лечение // Российский журнал кожных и венерических болезней. 2017. Т. 20, № 2. С. 112. EDN: WALKSW

[13] Wang D, Chong VC, Chong WS, Oon HH. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018;19(3):377-390. EDN: OVFWBQ doi: 10.1007/s40257-017-0338-1

[14] Wang D., Chong V.C., Chong W.S., Oon H.H. A review on pityriasis rubra pilaris // Am J Clin Dermatol. 2018. Vol. 19, N 3. P. 377-390. EDN: OVFWBQ doi: 10.1007/s40257-017-0338-1

[15] Roenneberg S, Biedermann T. Pityriasis rubra pilaris: Algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol. 2018;32(6):889-898. doi: 10.1111/jdv.14761

[16] Roenneberg S., Biedermann T. Pityriasis rubra pilaris: Algorithms for diagnosis and treatment // J Eur Acad Dermatol Venereol. 2018. Vol. 32, N 6. P. 889-898. doi: 10.1111/jdv.14761

[17] Vance P, Wyles S, Alavi A. Paraneoplastic pityriasis rubra pilaris preceding leukemia. Adv Skin Wound Care. 2022;35(6):1-4. doi: 10.1097/01.ASW.0000826828.53117.8c

[18] Vance P., Wyles S., Alavi A. Paraneoplastic pityriasis rubra pilaris preceding leukemia // Adv Skin Wound Care. 2022. Vol. 35, N 6. P. 1-4. doi: 10.1097/01.ASW.0000826828.53117.8c

[19] Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91(1):163-170. doi: 10.1016/j.ajhg.2012.05.010

[20] Fuchs-Telem D., Sarig O., van Steensel M.A., et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14 // Am J Hum Genet. 2012. Vol. 91, N 1. P. 163-170. doi: 10.1016/j.ajhg.2012.05.010

[21] Mellett M. Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease. Cell Immunol. 2020;354:104147. doi: 10.1016/j.cellimm.2020.104147

[22] Mellett M. Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease // Cell Immunol. 2020. Vol. 354. P. 104147. doi: 10.1016/j.cellimm.2020.104147

[23] Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5(1):105-112. doi: 10.1111/j.1365-2230.1980.tb01676.x

[24] Griffiths W.A. Pityriasis rubra pilaris // Clin Exp Dermatol. 1980. Vol. 5, N 1. P. 105-112. doi: 10.1111/j.1365-2230.1980.tb01676.x

[25] Miralles ES, Núñez M, De Las Heras ME, et al. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133(6):990-993. doi: 10.1111/j.1365-2133.1995.tb06939.x

[26] Miralles E.S., Núñez M., De Las Heras M.E., et al. Pityriasis rubra pilaris and human immunodeficiency virus infection // Br J Dermatol. 1995. Vol. 133, N 6. P. 990-993. doi: 10.1111/j.1365-2133.1995.tb06939.x

[27] Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: A review of diagnosis and treatment. Am J Clin Dermatol. 2010;11(3):157-170. doi: 10.2165/11530070-000000000-00000

[28] Klein A., Landthaler M., Karrer S. Pityriasis rubra pilaris: A review of diagnosis and treatment // Am J Clin Dermatol. 2010. Vol. 11, N 3. P. 157-170. doi: 10.2165/11530070-000000000-00000

[29] Cohen PR, Prystowsky JH. Pityriasis rubra pilaris: A review of diagnosis and treatment. J Am Acad Dermatol. 1989;20(5 Pt 1):801-807. doi: 10.1016/s0190-9622(89)70093-1

[30] Cohen P.R., Prystowsky J.H. Pityriasis rubra pilaris: A review of diagnosis and treatment // J Am Acad Dermatol. 1989. Vol. 20, N 5, Pt. 1. P. 801-807. doi: 10.1016/s0190-9622(89)70093-1

[31] Grebenyuk VN, Simanovskaya EYu, Zatorskaya NF, et al. Atypical juvenile type of the devergie disease. Russ J Clin Dermatol Venereol. 2019;18(5):572-578. EDN: HENYZJ doi: 10.17116/klinderma201918051572

[32] Гребенюк В.Н., Симановская Е.Ю., Заторская Н.Ф., и др. Ограниченный ювенильный тип болезни Девержи // Клиническая дерматология и венерология. 2019. Т. 18, № 5. С. 572-578. EDN: HENYZJ doi: 10.17116/klinderma201918051572

[33] De D, Dogra S, Narang T, et al. Pityriasis rubra pilaris in a HIV-positive patient (Type 6 PRP). Skinmed. 2008;7(1):47-50. doi: 10.1111/j.1540-9740.2007.07167.x

[34] De D., Dogra S., Narang T., et al. Pityriasis rubra pilaris in a HIV-positive patient (type 6 PRP) // Skinmed. 2008. Vol. 7, N 1. P. 47-50. doi: 10.1111/j.1540-9740.2007.07167.x

[35] Resnick SD, Murrell DF, Woosley JT. Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: An HIV-associated follicular syndrome? J Am Acad Dermatol. 1993;29(2 Pt 1):283. doi: 10.1016/s0190-9622(08)81854-3

[36] Resnick S.D., Murrell D.F., Woosley J.T. Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: An HIV-associated follicular syndrome? // J Am Acad Dermatol. 1993. Vol. 29, N 2, Pt. 1. P. 283. doi: 10.1016/s0190-9622(08)81854-3

[37] Aromolo IF, Pisapia A, Riva D, et al. COVID-19 induced pityriasis rubra pilaris: A superantigenic disease? J Eur Acad Dermatol Venereol. 2023;37(1):e26-e28. doi: 10.1111/jdv.18556

[38] Aromolo I.F., Pisapia A., Riva D., et al. COVID-19 induced pityriasis rubra pilaris: A superantigenic disease? // J Eur Acad Dermatol Venereol. 2023. Vol. 37, N 1. P. e26-e28. doi: 10.1111/jdv.18556

[39] Duncan P, Flood D, Dietz C. A rare post-infectious rash: pityriasis rubra pilaris after COVID-19 infection. Cureus. 2023;15(8):e43810. doi: 10.7759/cureus.43810

[40] Duncan P., Flood D., Dietz C. A rare post-infectious rash: pityriasis rubra pilaris after COVID-19 infection // Cureus. 2023. Vol. 15, N 8. P. e43810. doi: 10.7759/cureus.43810

[41] Kadylak D, Barańska-Rybak W. Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: A case report and its dermoscopic features. J Eur Acad Dermatol Venereol. 2021;35(10):e622-624. doi: 10.1111/jdv.17424

[42] Kadylak D., Barańska-Rybak W. Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: A case report and its dermoscopic features // J Eur Acad Dermatol Venereol. 2021. Vol. 35, N 10. P. e622-624. doi: 10.1111/jdv.17424

[43] Aguilar-Gamboa FR, Cubas-Alarcon D, Villegas-Chiroque M, Failoc-Rojas VE. Pityriasis rubra pilaris post-infection due COVID-19: Case report. Colomb Med (Cali). 2021;52(1):e7014577. doi: 10.25100/cm.v52i1.4577

[44] Aguilar-Gamboa F.R., Cubas-Alarcon D., Villegas-Chiroque M., Failoc-Rojas V.E. Pityriasis rubra pilaris post-infection due COVID-19: Case report // Colomb Med (Cali). 2021. Vol. 52, N 1. P. e7014577. doi: 10.25100/cm.v52i1.4577

[45] Larregue M, Champion R, Bressieux JM, et al. [Acute pityriasis rubra pilaris in the child. Apropos of 4 cases] (In French). Ann Dermatol Venereol. 1983;110(3):221-228.

[46] Larregue M., Champion R., Bressieux J.M., et al. [Acute pityriasis rubra pilaris in the child. Apropos of 4 cases] (In French) // Ann Dermatol Venereol. 1983. Vol. 110, N 3. P. 221-228.

[47] Ferrándiz-Pulido C, Bartralot R, Bassas P, et al. [Acute postinfectious pityriasis rubra pilaris: A superantigen-mediated dermatosis] (In Spanish). Actas Dermosifiliogr. 2009;100(8):706-709. doi: 10.1016/s0001-7310(09)72284-7

[48] Ferrándiz-Pulido C., Bartralot R., Bassas P., et al. [Acute postinfectious pityriasis rubra pilaris: A superantigen-mediated dermatosis] (In Spanish) // Actas Dermosifiliogr. 2009. Vol. 100, N 8. P. 706-709. doi: 10.1016/s0001-7310(09)72284-7

[49] Hamdy A, Leonardi A. Superantigens and SARS-CoV-2. Pathogens. 2022;11(4):390. EDN: KICAPH doi: 10.3390/pathogens11040390

[50] Hamdy A., Leonardi A. Superantigens and SARS-CoV-2 // Pathogens. 2022. Vol. 11, N 4. P. 390. EDN: KICAPH doi: 10.3390/pathogens11040390

[51] Cheng MH, Zhang S, Porritt RA, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci USA. 2020;117(41):25254-25262. EDN: ZKTHIS doi: 10.1073/pnas.2010722117

[52] Cheng M.H., Zhang S., Porritt R.A., et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation // Proc Natl Acad Sci USA. 2020. Vol. 117, N 41. P. 25254-25262. EDN: ZKTHIS doi: 10.1073/pnas.2010722117

[53] Chan H, Liu FT, Naguwa S. A review of pityriasis rubra pilaris and rheumatologic associations. Clin Dev Immunol. 2004;11(1):57-60. doi: 10.1080/10446670410001670008

[54] Chan H., Liu F.T., Naguwa S. A review of pityriasis rubra pilaris and rheumatologic associations // Clin Dev Immunol. 2004. Vol. 11, N 1. P. 57-60. doi: 10.1080/10446670410001670008

[55] Abduljawad M, Alsharif TH, Gronfula AG, et al. The effectiveness of anti-interleukin-17A treatment for pityriasis rubra pilaris: A systematic review. Cureus. 2023;15(6):e41125. doi: 10.7759/cureus.41125

[56] Abduljawad M., Alsharif T.H., Gronfula A.G., et al. The effectiveness of anti-interleukin-17A treatment for pityriasis rubra pilaris: A systematic review // Cureus. 2023. Vol. 15, N 6. P. e41125. doi: 10.7759/cureus.41125

[57] Sood S, Akuffo-Addo E, Yeung J, Mufti A. Biologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review. J Am Acad Dermatol. 2023;89(6):1306-1308. doi: 10.1016/j.jaad.2023.08.057

[58] Sood S., Akuffo-Addo E., Yeung J., Mufti A. Biologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review // J Am Acad Dermatol. 2023. Vol. 89, N 6. P. 1306-1308. doi: 10.1016/j.jaad.2023.08.057

[59] Wu KK, Dao H. Off-label dermatologic uses of IL-17 inhibitors. J Dermatolog Treat. 2022;33(1):41-47. doi: 10.1080/09546634.2020.1737638

[60] Wu K.K., Dao H. Off-label dermatologic uses of IL-17 inhibitors // J Dermatolog Treat. 2022. Vol. 33, N 1. P. 41-47. doi: 10.1080/09546634.2020.1737638

[61] Ringin SA, Daniel BS. Treatment modalities for pityriasis rubra pilaris subtypes: A review. J Dermatolog Treat. 2022;33(1):587-588. doi: 10.1080/09546634.2020.1729954

[62] Ringin S.A., Daniel B.S. Treatment modalities for pityriasis rubra pilaris subtypes: A review // J Dermatolog Treat. 2022. Vol. 33, N 1. P. 587-588. doi: 10.1080/09546634.2020.1729954

[63] Chu S, Michelle L, Ekelem C, et al. Oral isotretinoin for the treatment of dermatologic conditions other than acne: A systematic review and discussion of future directions. Arch Dermatol Res. 2021;313(6):391-430. doi: 10.1007/s00403-020-02152-4

[64] Chu S., Michelle L., Ekelem C., et al. Oral isotretinoin for the treatment of dermatologic conditions other than acne: A systematic review and discussion of future directions // Arch Dermatol Res. 2021. Vol. 313, N 6. P. 391-430. doi: 10.1007/s00403-020-02152-4

[65] Zhukova OV, Kruglova LS, Portnov VV, Kotenko KV. Ultra-violet therapy and system retinoid in the treatment of patients with disease of Devergie. Vestnik novyh medicinskih tehnologij (Online). 2014;(1). doi: 10.12737/5811

[66] Жукова О.В., Круглова Л.С., Портнов В.В., Котенко В.В. Ультрафиолетовая терапия и системные ретиноиды в лечении пациентов с болезнью Девержи // Вестник новых медицинских технологий. Электронное издание. 2014. № 1. doi: 10.12737/5811

[67] Boudreaux BW, Pincelli TP, Bhullar PK, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: A single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022;187(5):650-658. doi: 10.1111/bjd.21708

[68] Boudreaux B.W., Pincelli T.P., Bhullar P.K., et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: A single-arm clinical trial with transcriptomic analysis // Br J Dermatol. 2022. Vol. 187, N 5. P. 650-658. doi: 10.1111/bjd.21708

[69] Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: A review of the literature. J Am Acad Dermatol. 2018;79(2):353-359.e11. doi: 10.1016/j.jaad.2018.03.036

[70] Napolitano M., Abeni D., Didona B. Biologics for pityriasis rubra pilaris treatment: A review of the literature // J Am Acad Dermatol. 2018. Vol. 79, N 2. P. 353-359.e11. doi: 10.1016/j.jaad.2018.03.036

RIGHTS & PERMISSIONS

Eco-Vector